199 related articles for article (PubMed ID: 36980794)
1. Stromal Senescence following Treatment with the CDK4/6 Inhibitor Palbociclib Alters the Lung Metastatic Niche and Increases Metastasis of Drug-Resistant Mammary Cancer Cells.
Gallanis GT; Sharif GM; Schmidt MO; Friedland BN; Battina R; Rahhal R; Davis JE; Khan IS; Wellstein A; Riegel AT
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980794
[TBL] [Abstract][Full Text] [Related]
2. Cellular senescence in the response of HR
Klapp V; Buqué A; Bloy N; Sato A; Yamazaki T; Zhou XK; Formenti SC; Galluzzi L; Petroni G
J Transl Med; 2023 Feb; 21(1):110. PubMed ID: 36765430
[TBL] [Abstract][Full Text] [Related]
3. Biological Effects of Cyclin-Dependent Kinase Inhibitors Ribociclib, Palbociclib and Abemaciclib on Breast Cancer Bone Microenvironment.
Iuliani M; Simonetti S; Ribelli G; Napolitano A; Longo UG; Vincenzi B; Orsaria P; Denaro V; Tonini G; Santini D; Francesco P
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269621
[TBL] [Abstract][Full Text] [Related]
4. A Gene Panel Associated With Abemaciclib Utility in
Brett JO; Dubash TD; Johnson GN; Niemierko A; Mariotti V; Kim LSL; Xi J; Pandey A; Dunne S; Nasrazadani A; Lloyd MR; Kambadakone A; Spring LM; Micalizzi DS; Onozato ML; Che D; Nayar U; Brufsky A; Kalinsky K; Ma CX; O'Shaughnessy J; Han HS; Iafrate AJ; Ryan LY; Juric D; Moy B; Ellisen LW; Maheswaran S; Wagle N; Haber DA; Bardia A; Wander SA
JCO Precis Oncol; 2023 May; 7():e2200532. PubMed ID: 37141550
[TBL] [Abstract][Full Text] [Related]
5. Palbociclib-Induced Cellular Senescence Is Modulated by the mTOR Complex 1 and Autophagy.
Cayo A; Venturini W; Rebolledo-Mira D; Moore-Carrasco R; Herrada AA; Nova-Lamperti E; Valenzuela C; Brown NE
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298236
[TBL] [Abstract][Full Text] [Related]
6. Sustained mTORC1 activity during palbociclib-induced growth arrest triggers senescence in ER+ breast cancer cells.
Maskey RS; Wang F; Lehman E; Wang Y; Emmanuel N; Zhong W; Jin G; Abraham RT; Arndt KT; Myers JS; Mazurek A
Cell Cycle; 2021 Jan; 20(1):65-80. PubMed ID: 33356791
[TBL] [Abstract][Full Text] [Related]
7. Abemaciclib Is Effective in Palbociclib-Resistant Hormone Receptor-Positive Metastatic Breast Cancers.
Navarro-Yepes J; Kettner NM; Rao X; Bishop CS; Bui TN; Wingate HF; Singareeka Raghavendra A; Wang Y; Wang J; Sahin AA; Meric-Bernstam F; Hunt KK; Damodaran S; Tripathy D; Keyomarsi K
Cancer Res; 2023 Oct; 83(19):3264-3283. PubMed ID: 37384539
[TBL] [Abstract][Full Text] [Related]
8. Palbociclib Enhances Migration and Invasion of Cancer Cells via Senescence-Associated Secretory Phenotype-Related CCL5 in Non-Small-Cell Lung Cancer.
Kong P; Yang X; Zhang Y; Dong H; Liu X; Xu X; Zhang X; Shi Y; Hou M; Song B
J Oncol; 2022; 2022():2260625. PubMed ID: 37181790
[TBL] [Abstract][Full Text] [Related]
9. Palbociclib Effectively Halts Proliferation but Fails to Induce Senescence in Patient-Derived Glioma Stem Cells.
Morris-Hanon O; Marazita MC; Romorini L; Isaja L; Fernandez-Espinosa DD; Sevlever GE; Scassa ME; Videla-Richardson GA
Mol Neurobiol; 2019 Nov; 56(11):7810-7821. PubMed ID: 31124078
[TBL] [Abstract][Full Text] [Related]
10. Dual Targeting of CDK4/6 and BCL2 Pathways Augments Tumor Response in Estrogen Receptor-Positive Breast Cancer.
Whittle JR; Vaillant F; Surgenor E; Policheni AN; Giner G; Capaldo BD; Chen HR; Liu HK; Dekkers JF; Sachs N; Clevers H; Fellowes A; Green T; Xu H; Fox SB; Herold MJ; Smyth GK; Gray DHD; Visvader JE; Lindeman GJ
Clin Cancer Res; 2020 Aug; 26(15):4120-4134. PubMed ID: 32245900
[TBL] [Abstract][Full Text] [Related]
11. Nifuroxazide boosts the anticancer efficacy of palbociclib-induced senescence by dual inhibition of STAT3 and CDK2 in triple-negative breast cancer.
Wang X; Shi W; Wang X; Lu JJ; He P; Zhang H; Chen X
Cell Death Discov; 2023 Sep; 9(1):355. PubMed ID: 37752122
[TBL] [Abstract][Full Text] [Related]
12. Sunitinib facilitates metastatic breast cancer spreading by inducing endothelial cell senescence.
Wang D; Xiao F; Feng Z; Li M; Kong L; Huang L; Wei Y; Li H; Liu F; Zhang H; Zhang W
Breast Cancer Res; 2020 Sep; 22(1):103. PubMed ID: 32993785
[TBL] [Abstract][Full Text] [Related]
13. The CDK4/6 Inhibitor Palbociclib Induces Cell Senescence of High-grade Serous Ovarian Cancer Through Acetylation of p53.
Ye C; Cheng Y; Qian X; Zhong B; Ma J; Guo H
Biochem Genet; 2024 Feb; ():. PubMed ID: 38388849
[TBL] [Abstract][Full Text] [Related]
14. Comparison of Safety and Treatment Continuity of Palbociclib and Abemaciclib for Hormone Receptor-Positive, HER2-Negative Metastatic/Recurrent Breast Cancer.
Go M; Kimura M; Yamada S; Usami E; Noguchi Y; Yoshimura T
J Pharm Pract; 2024 Apr; ():8971900241247653. PubMed ID: 38652858
[No Abstract] [Full Text] [Related]
15. Indisulam synergizes with palbociclib to induce senescence through inhibition of CDK2 kinase activity.
Pogacar Z; Johnson JL; Krenning L; De Conti G; Jochems F; Lieftink C; Velds A; Wardak L; Groot K; Schepers A; Wang L; Song JY; van de Ven M; van Tellingen O; Medema RH; Beijersbergen RL; Bernards R; Leite de Oliveira R
PLoS One; 2022; 17(9):e0273182. PubMed ID: 36067171
[TBL] [Abstract][Full Text] [Related]
16. Thermal proteome profiling of breast cancer cells reveals proteasomal activation by CDK4/6 inhibitor palbociclib.
Miettinen TP; Peltier J; Härtlova A; Gierliński M; Jansen VM; Trost M; Björklund M
EMBO J; 2018 May; 37(10):. PubMed ID: 29669860
[TBL] [Abstract][Full Text] [Related]
17. Protective role of cytoplasmic p21Cip1/Waf1 in apoptosis of CDK4/6 inhibitor-induced senescence in breast cancer cells.
Kartika ID; Kotani H; Iida Y; Koyanagi A; Tanino R; Harada M
Cancer Med; 2021 Dec; 10(24):8988-8999. PubMed ID: 34761877
[TBL] [Abstract][Full Text] [Related]
18. Combination of palbociclib with navitoclax based-therapies enhances in vivo antitumoral activity in triple-negative breast cancer.
Estepa-Fernández A; García-Fernández A; Lérida-Viso A; Blandez JF; Galiana I; Sancenon-Galarza F; Orzáez M; Martínez-Máñez R
Pharmacol Res; 2023 Jan; 187():106628. PubMed ID: 36566002
[TBL] [Abstract][Full Text] [Related]
19. Clinico-Immunological Effects of a Single-Agent CDK4/6 Inhibitor in Advanced HR+/HER2- Breast Cancer Based on a Window of Opportunity Study.
D'Angelo A; Giudici F; Chapman R; Darlow J; Kilili H; Sobhani N; Cinelli M; Cappelletti MR; Strina C; Milani M; Generali D
Curr Issues Mol Biol; 2022 Sep; 44(9):4255-4267. PubMed ID: 36135204
[TBL] [Abstract][Full Text] [Related]
20. PALVEN: phase Ib trial of palbociclib, letrozole and venetoclax in estrogen receptor- and BCL2-positive advanced breast cancer.
Muttiah C; Whittle JR; Oakman C; Lindeman GJ
Future Oncol; 2022 May; 18(15):1805-1816. PubMed ID: 35187951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
